LT2448968T - Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus - Google Patents

Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus

Info

Publication number
LT2448968T
LT2448968T LTEP10739701.0T LT10739701T LT2448968T LT 2448968 T LT2448968 T LT 2448968T LT 10739701 T LT10739701 T LT 10739701T LT 2448968 T LT2448968 T LT 2448968T
Authority
LT
Lithuania
Prior art keywords
terminaltruncated
protofibrils
amyloid
oligomers
antibodies selective
Prior art date
Application number
LTEP10739701.0T
Other languages
English (en)
Lithuanian (lt)
Inventor
Pär GELLERFORS
Lars Lannfelt
Linda SÖDERBERG
Karin Tegerstedt
Original Assignee
Bioarctic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Ab filed Critical Bioarctic Ab
Publication of LT2448968T publication Critical patent/LT2448968T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
LTEP10739701.0T 2009-06-29 2010-06-29 Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus LT2448968T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22110509P 2009-06-29 2009-06-29
PCT/IB2010/052947 WO2011001366A1 (en) 2009-06-29 2010-06-29 N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's disease

Publications (1)

Publication Number Publication Date
LT2448968T true LT2448968T (lt) 2021-05-10

Family

ID=42832352

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP10739701.0T LT2448968T (lt) 2009-06-29 2010-06-29 Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus

Country Status (16)

Country Link
US (2) US20120100129A1 (enExample)
EP (2) EP3892633A1 (enExample)
JP (3) JP2012532094A (enExample)
AU (1) AU2010267640B2 (enExample)
CA (1) CA2765602C (enExample)
CY (1) CY1124034T1 (enExample)
DK (1) DK2448968T3 (enExample)
ES (1) ES2864049T3 (enExample)
HR (1) HRP20210611T1 (enExample)
HU (1) HUE053949T2 (enExample)
LT (1) LT2448968T (enExample)
PL (1) PL2448968T3 (enExample)
PT (1) PT2448968T (enExample)
SI (1) SI2448968T1 (enExample)
SM (1) SMT202100237T1 (enExample)
WO (1) WO2011001366A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
CN101421303B (zh) 2006-03-23 2013-06-12 生命北极神经科学公司 改进的初原纤维选择性抗体及其用途
HRP20180230T8 (hr) 2010-02-26 2021-04-30 Bioarctic Neuroscience Ab Protutijela koja se vežu na protofibrile i njihova upotreba u terapijskim i dijagnostičkim postupcima kod parkinsonove bolesti, demencije s lewyjevim tijelima i drugih alfa-sinukleinopatija
SG192805A1 (en) 2011-03-16 2013-09-30 Probiodrug Ag Diagnostic antibody assay
MY184890A (en) 2014-07-10 2021-04-29 Bioarctic Neuroscience Ab Improved a? protofibril binding antibodies
US11327080B2 (en) 2015-07-21 2022-05-10 BioArctic Neruoscience AB Method for treatment of traumatic brain injury targeting aggregated peptides
EP3484918A1 (en) 2016-07-14 2019-05-22 BioArctic Neuroscience AB Brain delivery protein
CA3070446A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. Treating cancer by blocking the interaction of tim-3 and its ligand
JP7541505B2 (ja) 2018-07-24 2024-08-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 アルツハイマー病の治療及び予防方法
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
US20220251518A1 (en) * 2019-07-08 2022-08-11 Terumo Kabushik Kaisha Hybridoma, method for making the same, monoclonal antibody, and method for making the same
WO2021055670A1 (en) 2019-09-20 2021-03-25 Avx Corporation Somatic cell-based electrical biosensor
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
FI4172199T3 (fi) 2020-06-26 2025-08-12 Bioarctic Ab Alfa-synukleiinin protofibrilliin sitoutuvat vasta-aineet
EP4367516A1 (en) 2021-07-09 2024-05-15 Eisai R&D Management Co., Ltd. Biomarkers for alzheimer's disease treatment
EP4395821A1 (en) 2021-08-30 2024-07-10 Eisai R&D Management Co., Ltd. Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
US20250377367A1 (en) 2022-02-02 2025-12-11 Eisai R&D Management Co., Ltd. Methods of treatment using p-tau181 level
KR20250134612A (ko) 2022-12-22 2025-09-11 바이오악틱 에이비 Abetape3에 결합하는 항체
US20250388664A1 (en) 2024-06-20 2025-12-25 Bioarctic Ab Bispecific binding molecule

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
WO2001010900A2 (en) * 1999-08-04 2001-02-15 University Of Southern California Globular assembly of amyloid beta protein and uses thereof
JP5362164B2 (ja) 2000-07-07 2013-12-11 バイオアークティック ニューロサイエンス アーベー アルツハイマー病の予防及び治療
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
EP1911765A3 (en) * 2002-07-24 2008-04-23 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with Beta-Amyloid formation and/or aggregation
EP2067789A1 (en) * 2004-04-13 2009-06-10 F. Hoffmann-La Roche Ag Anti-P selectin antibodies
GB0413726D0 (en) * 2004-06-18 2004-07-21 Lauras As Compounds
SE0401601D0 (sv) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
EA016357B1 (ru) * 2004-07-30 2012-04-30 Ринат Ньюросайенс Корп. Антитела, направленные против бета-амилоидного пептида, и способы их применения
CN101421303B (zh) * 2006-03-23 2013-06-12 生命北极神经科学公司 改进的初原纤维选择性抗体及其用途
MY158903A (en) * 2007-11-16 2016-11-30 Univ Rockefeller Antibodies specific for the protofibril form of beta-amyloid protein
ES2709048T3 (es) * 2008-04-29 2019-04-15 Bioarctic Ab Anticuerpos y vacunas para su uso en métodos terapéuticos y diagnósticos para trastornos relacionados con alfasinucleína

Also Published As

Publication number Publication date
JP2019218362A (ja) 2019-12-26
CA2765602A1 (en) 2011-01-06
US20120100129A1 (en) 2012-04-26
EP2448968A1 (en) 2012-05-09
CA2765602C (en) 2021-05-25
SI2448968T1 (sl) 2021-07-30
JP2012532094A (ja) 2012-12-13
EP3892633A1 (en) 2021-10-13
HRP20210611T1 (hr) 2021-05-28
PT2448968T (pt) 2021-04-30
AU2010267640B2 (en) 2015-03-05
JP6884025B2 (ja) 2021-06-09
ES2864049T3 (es) 2021-10-13
PL2448968T3 (pl) 2021-09-13
CY1124034T1 (el) 2022-05-27
HUE053949T2 (hu) 2021-08-30
SMT202100237T1 (it) 2021-05-07
EP2448968B1 (en) 2021-01-27
US20230295283A1 (en) 2023-09-21
JP2017197531A (ja) 2017-11-02
DK2448968T3 (da) 2021-04-12
AU2010267640A1 (en) 2012-01-19
WO2011001366A1 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
SMT202100237T1 (it) Anticorpi selettivi per protofibrille/oligomeri beta-amiloidi troncati n-terminali
ZA201202299B (en) Method for decreasing immunigenicity
GB0905140D0 (en) Method
EP2391894A4 (en) SYSTEM IN RELATIVE TIME
GB0902476D0 (en) Method
IL214600A0 (en) Process for preparing substituted 2-nitrobiphenyls
IL220357A0 (en) Process for preparing substituted 1-o-acyl-2-deoxy-2-fluoro-4-thio-beta-d-arabinofuranoses
IL215234A0 (en) Method for purifying recombinant fsh
GB0901444D0 (en) Method
PL2114996T3 (pl) Sposób otrzymywania hipoalergenów
IL208514A0 (en) Process for preparing substituted biphenylanilides
GB0905367D0 (en) Method
IL217192A0 (en) Biorefinery method
ZA201203155B (en) Method for isolating methylglycinenitrile-n,n-diacetonitrile
PL2284468T3 (pl) Sposób suszenia zrębków
GB0902034D0 (en) Method
GB0904946D0 (en) Method
GB0900560D0 (en) Method
EP2433942A4 (en) PROCESS FOR THE PREPARATION OF D-BIOTIN
GB0903026D0 (en) Novel method
GB0905332D0 (en) Method
GB2476082B (en) Improved base station architecture
IL199690A0 (en) Hanger for fhelf
GB0922292D0 (en) Novel Method
GB0919653D0 (en) Sutters for cars